BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023)

BeOne Medicines (ONC) has 8 years of Long-Term Deferred Tax data on file, last reported at $2.0 billion in Q4 2023.

• On a quarterly basis, Long-Term Deferred Tax fell 2.38% year-over-year to $2.0 billion in Q4 2023; TTM through Dec 2023 was $2.0 billion, a 2.38% decrease from a year earlier, with the FY2023 full-year figure at $2.0 billion, down 2.38% from the prior year.
• Long-Term Deferred Tax for Q4 2023 stood at $2.0 billion, down from $2.1 billion in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for ONC reached as high as $2.1 billion in Q4 2022 and fell as low as $30.5 million in Q1 2019.
• Historically, Long-Term Deferred Tax has averaged $328.5 million across 5 years, with a median of $66.0 million in 2020.
• Across the five-year window, Long-Term Deferred Tax soared 155.83% in 2019 and dropped 2.38% in 2023, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $37.9 million in 2019, then jumped by 74.07% to $66.0 million in 2020, then jumped by 61.98% to $106.8 million in 2021, then jumped by 1846.59% to $2.1 billion in 2022, then declined by 2.38% to $2.0 billion in 2023.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $2.0 billion in Q4 2023, $2.1 billion in Q4 2022, and $103.4 million in Q2 2022.